Letter to the editor

Current update on the protective effect of epicatechin in neurodegenerative diseases

Riya Thapa¹, Gaurav Gupta^1,2,3, Piyush Dave¹, Santosh Kumar Singh¹, Abhay Raizaday¹, Waleed Hassan Almalki⁴, Govind Vyas⁵, Sachin Kumar Singh^6,7, Kamal Dua^7,8, Yogendra Singh⁹[*]

¹School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura 302017, Jaipur, India

²Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

³Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India

⁴Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia

⁵Inva-Health Inc, Cranbury, NJ 08512, USA

⁶School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India

⁷Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia

⁸Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia

⁹Department of Pharmacology, Maharishi Arvind College of Pharmacy, Ambabari Circle, Ambabari, Jaipur, 302023, India

EXCLI J 2022;21:Doc897



Neurodegenerative diseases are characterized by the progressive loss of neural structures instead of the selective neuronal loss caused by metabolic or toxic disorders. Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis are among the several neurodegenerative diseases for which there is no treatment (Ruz et al., 2020[21]). New and better treatment strategies are urgently required to tackle these fatal illnesses. For example, epicatechin is one of the most prevalent and plentiful flavonoids (Figure 1(Fig. 1)). Numerous organs and tissues, including the heart, skeletal muscle, and neurons, have been studied, and epicatechin has been associated with mitochondrial improvement (Panneerselvam et al., 2013[19]). Epicatechin has been demonstrated to aid in treating neurodegenerative diseases, although there is little data to back this claim (Shaki et al., 2017[22]). The discoveries will also offer researchers a roadmap for developing neuroprotective drugs that are safe and effective (Table 1(Tab. 1); References in Table 1: Al-Amri et al., 2013[1]; Ali et al., 2021[2], 2022[3]; Avramovich-Tirosh et al., 2007[4]; Beasley et al., 2019[5]; Bitu Pinto et al., 2015[6]; Cano et al., 2021[7]; Cuevas et al., 2009[8]; Diaz et al., 2019[9]; Ehrnhoefer et al., 2006[10]; Ferruzzi et al., 2009[11]; Koh et al., 2006[12]; Kumar and Kumar, 2009[13]; Li et al., 2004[14]; Lim et al., 2013[15]; Mandel et al., 2004[16]; Nan et al., 2021[17]; N'Go et al., 2021[18]; Rubio-Osornio et al., 2015[20]; Shaki et al., 2017[22]; Siddique et al., 2014[23]; Tseng et al., 2020[24]; Wang et al., 2012[25]; Xu et al., 2006[26]; Ye et al., 2012[27]; Zhou et al., 2019[28]).

Conflict of interest

The authors declare no conflict of interest.

References